Stock Price & Analysis

Based on the provided data and current market status (closed), here's a concise analysis for TAK:

Technical Analysis The stock closed at $12.99 on Friday (Jan 24, 2025), showing a modest gain of 0.54% during regular trading hours. The RSI-14 reading of 42.95 indicates neutral momentum, slightly leaning towards oversold territory. The MACD at -0.12 suggests some bearish pressure in the near term.

Recent Developments

• Positive news: Health Canada recently authorized FRUZAQLA for treating metastatic colorectal cancer, which could provide new revenue opportunities.
• Potential concern: The FDA's ban on Red No. 3 (effective January 2027) affects Takeda's ADHD medication Vyvanse, though impact should be minimal as reformulation is possible.

Market Position The stock is currently trading below its 20-day moving average of $13.12, suggesting short-term weakness. However, the Fibonacci levels indicate potential support at $12.85, with resistance at $13.15.

Recommendation SELL. While Takeda has positive developments in its pipeline, technical indicators and price action suggest near-term weakness. The stock appears vulnerable to further downside with limited upward catalysts in the immediate term.

Based on the provided data and market context, here's the price prediction analysis for TAK stock in 2025:

TAK's stock price is expected to reach $14.50 by end of 2025, representing an 11.6% upside from current price of $12.99, driven by strong pipeline developments including recent FRUZAQLA approval in Canada and continued market expansion in North America which accounts for 71% of revenue.

The technical indicators show RSI at 42.95 and MACD at -0.12, suggesting the stock is currently in a neutral territory with slight bearish momentum, but the 20-day SMA of $13.12 indicates potential support level for upward movement.

Recent positive catalysts including Health Canada's market authorization for FRUZAQLA for treating metastatic colorectal cancer patients and strong Q3 performance with 36% YoY revenue growth provide fundamental support for the price target.

The S1 support level for TAK Stock is $12.85 ,The R1 resistant level for TAK Stock is $13.15.

As of the end of day on 2025-01-24, the price of TAK Stock was $12.99.

The target price for TAK Stock according to analyst rating is 14.80, with the highest price target at 14.80 and the lowest at 14.80. Analysts have a Moderate Buy rating on TAK Stock overall.

The market cap of TAK is $41.2B.

Based on the provided data, I'll analyze whether TAK is overvalued in 5 concise sentences:

Valuation Analysis TAK's current P/E ratio of 11.17x is significantly lower than its recent quarters (22.82x in Q4 2024), suggesting potential undervaluation. The company's EV/EBITDA multiple has declined from 10.42x to 7.84x, indicating improving operational efficiency relative to enterprise value. TAK's price-to-sales ratio of 0.71x and price-to-book ratio of 0.47x are both notably low, suggesting the stock is trading below its intrinsic value based on fundamental metrics.

Market Position and Catalysts Recent positive developments include Health Canada's authorization of FRUZAQLA for metastatic colorectal cancer treatment, though the company faces some headwinds with patent expirations for key drugs like Entyvio. The combination of attractive valuation metrics and positive regulatory developments suggests TAK is currently undervalued rather than overvalued.

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Based on the available data and market analysis, here is the price prediction for TAK stock by 2030:

TAK stock is projected to reach approximately $19-21 by 2030, driven by the company's strong pipeline in rare diseases and recent regulatory approvals like FRUZAQLA for metastatic colorectal cancer. The company's strategic focus on the North American market, which accounts for 71% of revenue, and expansion into specialty technologies through new facilities in Arizona, Japan and Germany positions it well for sustained growth.

The current technical indicators show an RSI of 42.95 and MACD of -0.12, suggesting the stock is neither overbought nor oversold at current levels, providing room for long-term appreciation. With the 20-day moving average at $13.12, the stock has established a stable base for future growth.

TAK has a total of 49281 employees.